Key result
Aspirin prophylaxis for primary prevention of cardiovascular disease in older persons lacks sufficient trial data, necessitating careful patient selection due to higher complication risks.
Why the study?
Does aspirin prophylaxis prevent cardiovascular disease in older persons?
Does aspirin prophylaxis prevent cardiovascular disease in older persons?
This review highlights the lack of evidence and complexities surrounding the use of aspirin for primary prevention of cardiovascular disease in older adults.
Reinforces individualized risk assessment before considering aspirin in older adults; leaves open the need for dedicated RCTs to define net benefit.
Cardiovascular disease is the leading cause of morbidity and mortality in older persons. The demographics among older persons are changing, with a dramatic increase in patients over the age of 80 years. Older persons are a unique socio–economic group, under-represented in primary prevention trials, with a higher risk of complications with aspirin prophylaxis. Given the high prevalence of cardiovascular disease and its complications in older persons, well-selected patients from this group may benefit from aspirin prophylaxis. However, there is a paucity of data regarding cardiovascular disease and its prevention in this population. We look at how to approach the complexities regarding the use of prophylactic aspirin in older persons.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2007) conducted a review in Cardiovascular disease. Aspirin was evaluated. Aspirin prophylaxis for primary prevention of cardiovascular disease in older persons lacks sufficient trial data, necessitating careful patient selection due to higher complication risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: